Alnylam Pharmaceuticals Inc. – Material Contracts Watch

EX-10.1

from 10-Q 8 pages Alnylam Pharmaceuticals, Inc. Performance Stock Unit Award Agreement Granted Under 2018 Stock Incentive Plan

12/34/56

EX-10.8

from 10-K 13 pages Alnylam Pharmaceuticals, Inc. Second Amended and Restated 2018 Stock Incentive Plan

12/34/56

EX-10.2

from 10-Q 4 pages Certain Information in This Document, Marked by [***], Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10)(iv). Such Excluded Information Is Not Material and Is the Type That the Registrant Treats as Private or Confidential. Amendment No. 1 to the Collaboration and License Agreement

12/34/56

EX-10.1

from 8-K 34 pages [Insert Dealer Name] [Insert Dealer Address] Date: September [ ], 2025 To: Alnylam Pharmaceuticals, Inc. 675 West Kendall Street, Henri A. Termeer Square Cambridge, Massachusetts 02142 From: [Insert Dealer Name] Subject: [Base][additional] Call Option Transaction

12/34/56

EX-10.2

from 10-Q 34 pages Alnylam Pharmaceuticals, Inc. Performance Stock Unit Award Agreement Granted Under 2018 Stock Incentive Plan

12/34/56

EX-10.1

from 10-Q 3 pages Alnylam Pharmaceuticals, Inc. Restricted Stock Unit Award Agreement for Non-Employee Directors (“Agreement”) Granted Under the Amended and Restated 2018 Stock Incentive Plan

12/34/56

EX-10.1

from 10-Q 5 pages Certain Information in This Document, Marked by [**], Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10)(iv). Such Excluded Information Is Not Material and Is the Type That the Registrant Treats as Private or Confidential. Amendment No. 3 to the Master Agreement

12/34/56

EX-10.4

from 10-Q 7 pages Alnylam Pharmaceuticals, Inc. Nonstatutory Stock Option Agreement Granted Under 2018 Stock Incentive Plan

12/34/56

EX-10.3

from 10-Q 8 pages Alnylam Pharmaceuticals, Inc. Nonstatutory Stock Option Agreement Granted Under 2018 Stock Incentive Plan

12/34/56

EX-10.2

from 10-Q 5 pages Alnylam Pharmaceuticals, Inc. Restricted Stock Unit Award Agreement Granted Under 2018 Stock Incentive Plan

12/34/56

EX-10.1

from 10-Q 7 pages Alnylam Pharmaceuticals, Inc. Performance Stock Unit Award Agreement Granted Under 2018 Stock Incentive Plan

12/34/56

EX-10.1

from 10-Q 4 pages Certain Information in This Document, Marked by [**], Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10)(iv). Such Excluded Information Is Not Material and Is the Type That the Registrant Treats as Private or Confidential. Amendment No. 2 to the Master Agreement

12/34/56

EX-10.1

from 8-K 9 pages February 8, 2024 Indrani Franchini at the Address on File With Alnylam Pharmaceuticals, Inc. Dear Indrani,

12/34/56

EX-10.1

from 10-Q 125 pages Collaboration and License Agreement by and Between Alnylam Pharmaceuticals, Inc. on the One Hand and F. Hoffmann-La Roche Ltd. and Genentech, Inc. on the Other Hand. Effective Date: July 21, 2023

12/34/56

EX-10.1

from 10-Q 6 pages Certain Information in This Document, Marked by [**], Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10)(iv). Such Excluded Information Is Not Material and Is the Type That the Registrant Treats as Private or Confidential. Amendment No. 1 to the Master Agreement

12/34/56

EX-10.1

from 8-K 7 pages Akshay K. Vaishnaw, M.D., PH.D. at the Address on File With Alnylam Pharmaceuticals, Inc. Dear Akshay: This Letter (This “Letter Agreement”) Sets Forth the Terms of Your Employment, Effective October 2, 2023 (The “Effective Date”), as Chief Innovation Officer of Alnylam Pharmaceuticals, Inc. (The “Company”). 1. Service as Chief Innovation Officer

12/34/56

EX-10.2

from 10-Q 4 pages Alnylam Pharmaceuticals, Inc. Restricted Stock Unit Award Agreement Granted Under 2018 Stock Incentive Plan

12/34/56

EX-10.1

from 10-Q 6 pages Alnylam Pharmaceuticals, Inc. Performance Stock Unit Award Agreement Granted Under 2018 Stock Incentive Plan

12/34/56

EX-10.60

from 10-K 2 pages Amendment to Purchase and Sale Agreement

12/34/56

EX-10.48

from 10-K 6 pages Certain Information in This Document, Marked by [**], Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10)(iv). Such Excluded Information Is Not Material and Is the Type That the Registrant Treats as Private or Confidential. Amendment No. 2 to License and Collaboration Agreement

12/34/56